Stay updated on Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial

Sign up to get notified when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.
    Difference
    2%
    Check dated 2025-06-19T19:45:07.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:18:44.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T05:58:50.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Difference
    1%
    Check dated 2025-05-22T02:31:23.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Difference
    1%
    Check dated 2025-05-07T19:21:38.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    1%
    Check dated 2025-04-30T13:56:03.000Z thumbnail image

Stay in the know with updates to Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.